These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18788437)

  • 1. [A case of severe pulmonary hypertension associated with COPD treated with epoprostenol].
    Ishikawa S; Yano S; Wakabayashi K; Tokuda Y; Kobayashi K; Ikeda T; Takeyama H
    Nihon Kokyuki Gakkai Zasshi; 2008 Aug; 46(8):660-6. PubMed ID: 18788437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of primary pulmonary hypertension treated by long-term continuous administration of epoprostenol].
    Yano S; Kobayashi K; Kato K; Tatsukawa T; Ikeda T
    Nihon Kokyuki Gakkai Zasshi; 2005 Jun; 43(6):354-9. PubMed ID: 15997785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
    Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
    Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.
    Wang L; Jin YZ; Zhao QH; Jiang R; Wu WH; Gong SG; He J; Liu JM; Jing ZC
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3353-3360. PubMed ID: 29200842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
    Maki H; Yao A; Inaba T; Shiga T; Hatano M; Kinugawa K; Yamashita T; Aizawa T; Nagai R
    Int Heart J; 2011; 52(5):323-6. PubMed ID: 22008445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
    Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
    Shimizu M; Imanishi J; Takano T; Miwa Y
    Intern Med; 2011; 50(20):2341-6. PubMed ID: 22001462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
    Chin KM; Channick RN; Kim NH; Rubin LJ
    Chest; 2007 Sep; 132(3):786-92. PubMed ID: 17646224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia.
    Rugolotto S; Errico G; Beghini R; Ilic S; Richelli C; Padovani EM
    Minerva Pediatr; 2006 Oct; 58(5):491-4. PubMed ID: 17008861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol.
    Akagi S; Matsubara H; Miyaji K; Ikeda E; Dan K; Tokunaga N; Hisamatsu K; Munemasa M; Fujimoto Y; Ohe T
    Circ J; 2008 Jul; 72(7):1142-6. PubMed ID: 18577825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
    Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
    Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension.
    Hirabayashi A; Miyaji K; Akagi T
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):688-91. PubMed ID: 19133673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
    Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
    Tam DH; Farber HW
    Am J Hematol; 2006 Jun; 81(6):443-7. PubMed ID: 16680745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.